Jan 03, 2011 08:30 ET – Marina Biotech Announces Allowance of Patent Covering DiLA2 Delivery Platform From U.S. Patent Office
Obtains Additional Patent Protection for Its RNAi-Based Delivery Technologies
BOTHELL, WA–(Marketwire – January 3, 2011) – Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for patent application U.S. 12/114,284 covering its proprietary DiLA2 delivery platform. The allowed claims provide patent protection for a broad array of DiLA2 molecules as well as formulations based on these DiLA2 molecules, including liposomes, emulsions and micellar dispersions; and pharmaceutical compositions of DiLA2 molecules with therapeutic nucleic acids, including siRNA, microRNA, meroduplex siRNA (3-stranded siRNA), single-stranded RNA and short-hairpin RNA (shRNA); and finally, methods for treating human disease using the DiLA2 delivery platform. (read the entire release… )
Subscribe to the miRNA blog
Thank you for subscribing.
Something went wrong.
